Although potential biomarkers such as PD-L1 expression levels, tumor mutation burden (TMB), and tumor-infiltrating T cells have been identified, their clinical validation remains contentious (Yap et al. 2021; Khan et al. 2023; Jardim et al. 2021). Here, CD274 is linked to neoplasm.